Allergy Therapeutics (LON:AGY)‘s stock had its “buy” rating restated by stock analysts at Numis Securities in a report released on Tuesday. They presently have a GBX 45 ($0.61) price objective on the stock. Numis Securities’ target price would suggest a potential upside of 59.29% from the stock’s previous close.

A number of other analysts also recently issued reports on AGY. FinnCap reaffirmed a “buy” rating and issued a GBX 47 ($0.63) price objective on shares of Allergy Therapeutics in a research note on Friday, October 20th. Panmure Gordon restated a “buy” rating on shares of Allergy Therapeutics in a report on Monday, September 18th.

Shares of Allergy Therapeutics (LON:AGY) traded up GBX 0.24 ($0.00) during trading hours on Tuesday, reaching GBX 28.25 ($0.38). The company’s stock had a trading volume of 62,460 shares, compared to its average volume of 136,330. Allergy Therapeutics has a fifty-two week low of GBX 19.50 ($0.26) and a fifty-two week high of GBX 39.50 ($0.53).

In other Allergy Therapeutics news, insider Tunde Otulana acquired 25,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 11th. The stock was bought at an average price of GBX 51 ($0.69) per share, for a total transaction of £12,750 ($17,160.16).

WARNING: “Allergy Therapeutics’ (AGY) Buy Rating Reiterated at Numis Securities” was posted by American Banking News and is owned by of American Banking News. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this story can be accessed at

About Allergy Therapeutics

Allergy Therapeutics Plc is a pharmaceutical company. The Company focuses on the treatment and prevention of allergy with aluminum-free products. The Company’s segments are Central Europe, which includes segments, such as Germany, Australia, Switzerland and the Netherlands; Southern Europe, which includes Italy and Spain; the United Kingdom, and Rest of World.

Receive News & Ratings for Allergy Therapeutics plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics plc and related companies with's FREE daily email newsletter.